Alto Neuroscience Overview
- Year Founded
-
2019
- Status
-
Public
- Employees
-
68
- Stock Symbol
-
ANRO
- Share Price
-
$29.54
- (As of Friday Closing)
Alto Neuroscience General Information
Description
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
Contact Information
Website
www.altoneuroscience.comCorporate Office
- 650 Castro Street
- Suite 450
- Mountain View, CA 94041
- United States
Corporate Office
- 650 Castro Street
- Suite 450
- Mountain View, CA 94041
- United States
Alto Neuroscience Timeline
Alto Neuroscience Stock Performance
As of 13-Nov-2026, Alto Neuroscience’s stock price is $29.54. Its current market cap is $1.18B with 40.1M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $29.54 | $30.62 | $10.80 - $37.48 | $1.18B | 40.1M | 602K | -$2.32 |
Alto Neuroscience Financials Summary
As of 30-Sep-2026, Alto Neuroscience has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 781,412 | 442,687 | (50,831) | |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (100,235) | (66,711) | (68,405) | (36,911) |
| Net Income | (95,181) | (63,238) | (61,431) | (36,305) |
| Total Assets | 326,505 | 184,689 | 177,542 | 86,628 |
| Total Debt | 18,021 | 23,958 | 16,944 | 9,986 |
Alto Neuroscience Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Alto Neuroscience Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Alto Neuroscience Comparisons
Industry
Financing
Details
Alto Neuroscience Competitors (7)
One of Alto Neuroscience’s 7 competitors is Praxis (Drug Discovery), a Formerly VC-backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Praxis (Drug Discovery) | Formerly VC-backed | Boston, MA | ||||
| Neumora | Formerly VC-backed | Watertown, MA | ||||
| Minerva Neurosciences | Formerly VC-backed | Burlington, MA | ||||
| Xenon Pharmaceuticals | Formerly VC-backed | Burnaby, Canada | ||||
| Relmada Therapeutics | Formerly VC-backed | Coral Gables, FL |
Alto Neuroscience Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Alto Neuroscience Patents
Alto Neuroscience Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026217952-A1 | Treatment of neuropsychiatric disorders with tilivapram | Pending | 10-Apr-2025 | ||
| US-20260232262-A1 | Placebo response prediction for psychiatric patients | Pending | 12-Feb-2025 | ||
| WO-2026174029-A1 | Placebo response prediction for psychiatric patients | Pending | 12-Feb-2025 | ||
| US-12594028-B1 | Eeg montage for facilitating selection of drug treatment in patients suffering from psychiatric disorders | Active | 06-Feb-2025 | ||
| US-20260224165-A1 | Eeg montage for facilitating selection of drug treatment in patients suffering from psychiatric disorders | Pending | 06-Feb-2025 | A61B5/6814 |
Alto Neuroscience Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Alto Neuroscience Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Alto Neuroscience ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Alto Neuroscience FAQs
-
When was Alto Neuroscience founded?
Alto Neuroscience was founded in 2019.
-
Where is Alto Neuroscience headquartered?
Alto Neuroscience is headquartered in Mountain View, CA.
-
What is the size of Alto Neuroscience?
Alto Neuroscience has 68 total employees.
-
What industry is Alto Neuroscience in?
Alto Neuroscience’s primary industry is Drug Discovery.
-
Is Alto Neuroscience a private or public company?
Alto Neuroscience is a Public company.
-
What is Alto Neuroscience’s stock symbol?
The ticker symbol for Alto Neuroscience is ANRO.
-
What is the current stock price of Alto Neuroscience?
As of 13-Nov-2026 the stock price of Alto Neuroscience is $29.54.
-
What is the current market cap of Alto Neuroscience?
The current market capitalization of Alto Neuroscience is $1.18B.
-
Who are Alto Neuroscience’s competitors?
Praxis (Drug Discovery), Neumora, Minerva Neurosciences, Xenon Pharmaceuticals, and Relmada Therapeutics are some of the 7 competitors of Alto Neuroscience.
-
What is Alto Neuroscience’s annual earnings per share (EPS)?
Alto Neuroscience’s EPS for 12 months was -$2.32.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
